University of Ioannina
Μοριακή ανάλυση των μεταλλάξεων των γονιδίων υποδοχέα της ερυθροποιητίνης και της JAK2 κινάσης σε ασθενείς με οικογενή πολυερυθραιμία και μυελοϋπερπλαστικά σύνδρομα
Abstract
dc:descriptionErythropoietin is a cytokine that plays a crucial role in the production and apoptosis of the red cell lineage. Erytropoietin acts through the erythropoietin receptors which are mainly sited at the CFU-E red cell progenitors, as well as at the BFU-E red cell progenitors, the CNS cells and the cardiac cells. After the connection of Epo with Epo-R, Epo’s message is transducted though the JAK 2 kinase and STAT 5 molecules. The signal is transmitted into the nuclear, and affects the activity of die bcl-x gene, an inhibitor of apoptosis of the red cell series. Today, it is widely known that Polycythemia Vera, Idiopathic Thrombocytosis and Idiopathic Myelofibrosis, which are the bcr/abl negative MDS, is seriously influenced by Epo, Epo-R and JAK 2 kinase. Familial and Congenital Polycythemia is one of the types of Primary Erythrocytosis. It has several different molecular, laboratory and clinical parameter in comparison with Polycythemia Vera. We know that the pathogenesis of the disease is caused partly by the mutations on the EpoR. It is though that these mutations lead to elevated proliferation of the red cell progenitors and to the characteristic clinical presentation. Until today, 13 mutations of the Epo-R have been described, from which, 10 are directly connected with the pathogenesis of Familial Polycythemia. In this study, we tried to trase any of Epo-R mutations in Greek members with diagnostic criteria for the disease and their first degree relatives. Unfortunately we did not succeed in discovering any of those mutations. As the Epo’s molecular activity is performed through the Epo-R and the JAK 2 kinase, and guided by the international literature, we investigated our patients suffering from both MDS and Familial Polycythemia, in terms of the presentation of the JAK 2 V617F mutation. In 2005 this mutation was detected in the majority of patients with PV and in half patients with IT and IM and seems to be the key for the pathogenesis ofthe bcr/abl negative MPDs. The V617F mutation takes place in the in the cDNA area that codes the pseudokinase (JH2 homologue domain) of the JAK 2 molecule. In the 1849 position there is a substitution of the nucleoside guanine (G) to thymine (I). This change leads to the substitution of the aminoacid valine to phenylalanine in the position 617 in JFI2 domain of JAK 2 molecule (Val617Phe, V617F). This mutation leads to downregulatoin of action of JH2 domain, which normally inhibits the JAK 2 kinase activity. In such a case, increased kinase activity is observed even in the absence of Epo. The final result is the inhibition of apoptosis and the proliferation of the blood cell precursors, more of less the same disorder that happens in CML, by the action of bcr/abl. Today, the JAK 2 V617F mutation is detected in more than 95% of the PV patients and in almost half of the IT and IM patients. It is widely suspected that the presense of the mutation affects the clinical manifestations of the PV and IT, mainly expressed by the high incidence of throbotic and hemorrhagic episodes, as well as the transition to IM and acute Leukemia. In this study we did not detect any mutation of JAK 2 V617F in the familial polycythemia patients. Besides, the mutation was found in 62% of PV patients, in 45% of IT patients and in 60% for IM patients. Furthermore, we noticed a significant positive statistical connection between the number of platelets and the presence of V617F in PV patients. The same patients expressed positive correlation in the coincidence of thrombotic and hemorrhagic episodes and the presence of V617F mutation. The finding of homozygosity of JAK 2 V617F in 22% of PV patients, which is conformed by multiple references, reveals the activity of the mitotic recombination of DNA and the presence of mutant subclones. On the other hand, there were no homozygous IT and IM patients. The transformation of homozygous form of V617F into eterozygous, in a single PV patient, after the use of interferon, reveals the theurapetic action of this molecule in the MDS and the possibility of high molecular and clinical response after treatment. There are some attempts of management of MPDs, through the inhibition of JAK 2 kinase activity, but we are still at beginning of our efforts. Finally, it is sure that JAK 2 kinase is probably the key molecule in discovering and understanding the molecular pathogenesis of MPDs. It is more than helpful in achieving diagnosis, prognosis and theurapetic response of MPDs. Now we have the opportunity to reach a theurapeutic management of the diseases using the current therapies, or discovering new regimens that change the natural history and prognosis of MPDs.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bourantas, Lambros
- Μπουραντάς, Λάμπρος
Subjects
dc:subject × 20- Υποδοχείς ερυθροποιητίνης
- JAK-2 κινάση
- Οικογενής πολυερυθραιμία
- Μυελοϋπερπλαστικά σύνδρομα
- Αληθής πολυερυθραιμία
- Ιδιοπαθής θρομβοκυττάρωση
- Ϊδιοπαθής μυελοΐνωση
- Μετάλλαξη JAK-2 V617F
- Erythropoietin receptors
- JAK-2 kinase
- Familial polycythemia
- myeloproliferative syndromes
- Polycythemia vera
- Idiopathic thromboeythemia
- Idiopathic myelofibrosis
- JAK-2 V617F mutation
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21489